Literature DB >> 16014319

Deficient inhibition of return in schizophrenia-further evidence from an independent sample.

Euphrosyne Gouzoulis-Mayfrank1, Susanne Arnold, Karsten Heekeren.   

Abstract

Previous studies on spatial orienting of attention in schizophrenia demonstrated a deficit of Inhibition of Return (IOR). However, other studies reported a delay in the manifestation, but an overall normal amount of IOR in patients with schizophrenia. However, the latter studies used a cue-back manipulation which is known to reinstate or speed up IOR. Hence, it is not clear whether even very long cue target intervals would allow IOR to develop in patients with schizophrenia in the absence of a cue-back manipulation. The aim of the present study was to study IOR in patients with schizophrenia using a single cue paradigm and a very long cue target interval of >1 s in order to differentiate between blunted and delayed IOR. We examined 32 inpatients with schizophrenia and 16 healthy controls with a covert orienting of attention task (COVAT) with non-predictive peripheral cues and three stimulus onset asynchronies (SOA: 100 ms, 800 ms and 1050 ms). We found a lack of Inhibition of Return (IOR) in patients with schizophrenia with both long SOAs of 800 and 1050 ms. As in a previous study of our group, the IOR deficit was unrelated to psychopathology, length of illness, number of previous psychotic episodes and type of neuroleptic medication. In summary, our study confirms and extends previous reports of deficient IOR in patients with schizophrenia. IOR seems to be not just delayed, but rather profoundly disturbed in schizophrenia. Deficient IOR in patients with schizophrenia might be viewed as a trait or alternatively as a vulnerability marker of the disorder.

Entities:  

Mesh:

Year:  2005        PMID: 16014319     DOI: 10.1016/j.pnpbp.2005.06.016

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  7 in total

1.  Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.

Authors:  Boris B Quednow; Michael Kometer; Mark A Geyer; Franz X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  The inter-trial effects of stimulus and saccadic direction on prosaccades and antisaccades, in controls and schizophrenia patients.

Authors:  Jason J S Barton; Donald C Goff; Dara S Manoach
Journal:  Exp Brain Res       Date:  2006-04-27       Impact factor: 1.972

3.  Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis.

Authors:  Jörg Daumann; Karsten Heekeren; Anna Neukirch; Christiane M Thiel; Walter Möller-Hartmann; Euphrosyne Gouzoulis-Mayfrank
Journal:  Psychopharmacology (Berl)       Date:  2008-07-24       Impact factor: 4.530

4.  Gaze cueing of attention in schizophrenia: individual differences in neuropsychological functioning and symptoms.

Authors:  Paul G Nestor; Kristy Klein; Marc Pomplun; Margaret Niznikiewicz; Robert W McCarley
Journal:  J Clin Exp Neuropsychol       Date:  2009-06-18       Impact factor: 2.475

5.  Auditory orienting and inhibition of return in schizophrenia: a functional magnetic resonance imaging study.

Authors:  Christopher C Abbott; Flannery Merideth; David Ruhl; Zhen Yang; Vincent P Clark; Vince D Calhoun; Faith M Hanlon; Andrew R Mayer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-12-30       Impact factor: 5.067

6.  Neural correlates of the preserved inhibition of return in schizophrenia.

Authors:  Yingying Tang; Yan Li; Kaiming Zhuo; Yan Wang; Liwei Liao; Zhenhua Song; Hui Li; Xiaoduo Fan; Donald C Goff; Jijun Wang; Yifeng Xu; Dengtang Liu
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

7.  The Different Inhibition of Return (IOR) Effects of Emergency Managerial Experts and Novices: An Event-Related Potentials Study.

Authors:  Rong Cao; Lü Wu; Shuzhen Wang
Journal:  Front Behav Neurosci       Date:  2017-05-22       Impact factor: 3.558

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.